Genmab A (GMAB) EBITDA: 2018-2021
- Genmab A's EBITDA rose 370.36% to $135.01 in Q2 2021 from the same period last year, while for Jun 2021 it was $278.86, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $277.1 million for FY2020, which is 22.66% up from last year.
- Latest data reveals that Genmab A reported EBITDA of $135.01 as of Q2 2021, which was up 129.68% from $58.78 recorded in Q4 2020.
- In the past 5 years, Genmab A's EBITDA ranged from a high of $19.9 million in Q4 2018 and a low of -$9.0 million during Q2 2019.
- For the 3-year period, Genmab A's EBITDA averaged around -$1.8 million, with its median value being $56.37 (2019).
- Per our database at Business Quant, Genmab A's EBITDA plummeted by 100.00% in 2019 and then skyrocketed by 370.36% in 2021.
- Genmab A's EBITDA (Quarterly) stood at $19.9 million in 2018, then slumped by 100.00% to $56.37 in 2019, then rose by 4.29% to $58.78 in 2020, then soared by 370.36% to $135.01 in 2021.
- Its last three reported values are $135.01 in Q2 2021, $58.78 for Q4 2020, and $28.70 during Q2 2020.
